Objectives

- Review clinical trial design at planning stage.

- Monitor ongoing trials: adverse events, compliance, community priorities.

- Stay informed of interim results.

- Represent PLWHA interests, in particular clinical trial participants.

- Review informed consent forms (content, language).

- Promote best practice procedures and ethics.

- Represent patients perspective within investigator / advisory meetings, DSMBs.

- Promote universal access to treatment in WHO Europe countries.

- Promote access to treatment for vulnerable groups.

- Support efforts to harmonise safety reporting in Europe, and better involvement of patients in AE reporting.

- Promote research NPT, IBT.

- Promote development of new & effective therapies for hep/TB co-infected patients.

- Address the specific needs of vulnerable populations.

- Work proactively, anticipating treatment needs of HIV-positive people.

- Benchmark EATG influence on clinical research and drug development, review and identify the most needed changes and effective methods, and develop a strategy for scaling up.